Ipilimumab in Extensive Stage Small Cell Lung Cancer

Drug class	Target	Agent	Diseases	Line of Therapy	Status	Source
CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody	CTLA-4	ipilimumab (Yervoy)	small cell lung cancer	metastatic	Trials complete with results	Reck et al. 2013; Antonia et al. 2015

The efficacy and safety of CTLA-4 inhibitors for the treatment of patients with small cell lung cancer (SCLC) is currently under investigation. Ipilimumab has shown potential in treating patients with extensive SCLC in a phase II trial (NCT00527735; Reck et al. 2013).

In a phase I/II study comparing treatment with nivolumab alone andversus nivolumab in combination with ipilimumab in patients with recurrent SCLC, the combination arm demonstrated higher response rates than the single agent arm (CA209-032; Antonia et al. 2015).

Reference	Study Type / Phase	Line of Treatment	Treatment Agent	# Patients in Study	Response Rate	PFS (months)	OS (months)
Reck et al. 2013	Phase II	1st line	concurrent ipilimumab + carboplatin + paclitaxel	43	33%	3.9	9.1
			phased ipilimumab + carboplatin + paclitaxel	42	57%	5.2	12.5
			carboplatin + paclitaxel	45	49%	5.2	10.5
Antonia et al. 2015 (CA209-032)	Phase I/II	2nd line	nivolumab	40	15%
			nivolumab + ipilimumab	35	25%

NOTE: OS = overall survival; PFS = progression-free survival

Contributors: Wade T. Iams, M.D., Douglas Johnson, M.D., Christine M. Lovly, M.D., Ph.D.

Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.mycancergenome.org/content/molecular-medicine/c2654-small-cell-lung-cancer/ (Updated September 3).